Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance : a case series
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Critical care (London, England) - 24(2020), 1 vom: 25. Sept., Seite 578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fu, Dian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 08.10.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13054-020-03288-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315486090 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315486090 | ||
| 003 | DE-627 | ||
| 005 | 20231225155023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-020-03288-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315486090 | ||
| 035 | |a (NLM)32977854 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fu, Dian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance |b a case series |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.10.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a viral RNA persistence | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 700 | 1 | |a Cao, Ruiyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Jiqiu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 24(2020), 1 vom: 25. Sept., Seite 578 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2020 |g number:1 |g day:25 |g month:09 |g pages:578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-020-03288-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2020 |e 1 |b 25 |c 09 |h 578 | ||